Viral Vector Manufacturing

Viral Vector Manufacturing

Global Viral Vector Manufacturing Market to Reach $1.5 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 18.5% over the analysis period 2020-2027. Retroviral Vectors, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$547.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $265.6 Million, While China is Forecast to Grow at 21.9% CAGR

The Viral Vector Manufacturing market in the U.S. is estimated at US$265.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$58 Million by the year 2027 trailing a CAGR of 21.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.Adeno-associated Viral Vectors Segment to Record 19.8% CAGR

In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.5 Million in the year 2020 will reach a projected size of US$316.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 80 Featured) -

  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • Cobra Biologics Ltd.
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies
  • Genelux Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • MaxCyte, Inc.
  • Merck KGaA
  • Novasep Inc.
  • Oxford BioMedica plc
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Biolabs
  • Vigene Biosciences, Inc.
  • Virovek, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of COVID-19 Pandemic and Looming Global Recession
With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit
An Introduction to Viral Vector Manufacturing
Applications of Viral Vectors
Types of Viral Vectors
Global Viral Vector Manufacturing Market: Prospects & Outlook
Competition
COVID-19 Pandemic Puts Pressure on Already Constrained Viral Vector Manufacturing Capacity
A Glance at Select Investments in Expanding Viral Vector Manufacturing Capacity
Recent Market Activity
Viral Vector Manufacturing – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects
Gene Therapy Set to Witness Rapid Growth Post COVID-19
Viral Vectors Lead the Gene Therapy Market
Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
Lentiviral Vectors Witness Increased Interest for Gene Therapy
Funding Support for Gene Therapy Development Presents Market Opportunities
Complexity in Viral Vector Production for Gene therapies
Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
Number of New Cancer Cases and Deaths (in Million) by Region for 2018
Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
Rising Significance of Viral Vectors in New Vaccine Development
Adenovirus-based Vaccines: Evolution Over the Years
Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects for Viral Vector Manufacturing
COVID-19 Vaccines Under Development
Vaccines in Pipeline by Technology
Vaccine Technologies in Pre-Clinical Studies
Replicating and Non-Replicating Viral Vector-Based Vaccines
Non-Replicating Viral vector Vaccine in Clinical Development: As on December 2nd, 2020
Replicating Viral vector Vaccine Candidate in Clinical Development: As on December 2nd, 2020
Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19
Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome
Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
New Trends for Optimizing Workflow Using Viral Vectors
Production Workflow & Viral Vectors
Closed-System-Adherent Culture of Cells: Recent Advances
Limitations in Viral Vector Manufacturing Impact Market
Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 3: World 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 6: World 11-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 9: World 11-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 12: World 11-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 15: World 11-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 18: World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 21: World 11-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 24: World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 27: World 11-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 30: World 11-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 33: World 11-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 34: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: USA Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 36: USA 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 37: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: USA Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 39: USA 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 40: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: USA Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 42: USA 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
CANADA
TABLE 43: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: Canada Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 45: Canada 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 46: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: Canada Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 48: Canada 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 49: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Canada Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 51: Canada 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
JAPAN
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 52: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Japan Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 54: Japan 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 55: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: Japan Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 57: Japan 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 58: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: Japan Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 60: Japan 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
CHINA
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 61: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: China Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 63: China 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 64: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: China Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 66: China 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 67: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: China Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 69: China 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
EUROPE
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 70: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 71: Europe Historic Review for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 72: Europe 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2021 & 2027
TABLE 73: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 75: Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 76: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 78: Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 79: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 81: Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
FRANCE
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 82: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: France Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 84: France 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 85: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: France Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 87: France 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 88: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: France Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 90: France 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
GERMANY
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 91: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Germany Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 93: Germany 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 94: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: Germany Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 96: Germany 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 97: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: Germany Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 99: Germany 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
ITALY
TABLE 100: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 101: Italy Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 102: Italy 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 103: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 104: Italy Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 105: Italy 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 106: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 107: Italy Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 108: Italy 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
UNITED KINGDOM
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 109: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 110: UK Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 111: UK 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 112: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 113: UK Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 114: UK 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 115: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 116: UK Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 117: UK 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
REST OF EUROPE
TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 119: Rest of Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 120: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 121: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 122: Rest of Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 123: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 125: Rest of Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 126: Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
ASIA-PACIFIC
Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 127: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 128: Asia-Pacific Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 129: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 131: Asia-Pacific Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 132: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 133: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 134: Asia-Pacific Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 135: Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
REST OF WORLD
TABLE 136: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 137: Rest of World Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 138: Rest of World 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2021 & 2027
TABLE 139: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 140: Rest of World Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 141: Rest of World 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2021 & 2027
TABLE 142: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 143: Rest of World Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 144: Rest of World 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 80

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings